ADAMTS13 and thrombotic thrombocytopenic purpura: With improved diagnostic awareness, ADAMTS13 activity and its inhibitor testing, and the use of rituximab for TTP patients, from 2006 to 2021, the mortality rate was lower than that of 2001 to 2005, but no downward trend was observed year by year, which means there is no obvious “time effect” on mortality in this cohort.